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Abstract: Dengue virus (DV) infection can cause mild dengue fever or severe dengue hemorrhage 
fever and dengue shock syndrome. Macrophage migration inhibitory factor (MIF) is a cytokine that 
plays an important role in the modulation of inflammatory and immune responses and serum levels of 
MIF are correlated with disease severity in dengue patients. However, the mechanism that induces MIF 
production during DV infection is unclear. In this study, we showed that DV infection, but not UV-
inactivated DV stimulation, dose-and time-dependently induced MIF secretion in human A649 
epithelial cells. MIF promoter assays and RT-PCR demonstrated that MIF gene transcription was 
activated during DV infection. Furthermore, DV infection induced NF-κB activation, and the    NF-κB 
inhibitors dexamethasone and curcumin inhibited DV-induced MIF production. Finally, we found that 
different cells have different abilities to release MIF after DV infection. Interestingly, DV infection and 
MIF production in the human monocytic cell line THP-1 and peripheral blood mononuclear cells 
increased in the presence of antibodies against DV. Taken together, these results suggest that DV 
infection of human cells induces NF-κB activation and MIF production, which can be increased in the 
presence of pre-existing antibodies. 
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INTRODUCTION 
  Dengue viruses (DV) are mosquito-borne 
flaviviruses subgrouped into four antigenically related 
serotypes: DV types 1, 2, 3, and 4
[1]. It is estimated that 
over 50 million DV infections occur globally each 
year
[2]. DV infection generally causes mild symptoms 
such as fever, headache, and muscle and joint pain, 
which is called dengue fever (DF). In some cases, 
especially during secondary infection with a different 
serotype of DV, the infection may progress to dengue 
hemorrhagic fever (DHF) or dengue shock syndrome 
(DSS)
[3]. DHF is a severe febrile disease characterized 
by abnormalities in homeostasis and increased capillary 
leakage that can progress to hypovolemic shock 
(DSS)
[4]. Even though the process leading to DHF/DSS 
is not fully understood, antibody-dependent 
enhancement (ADE) has been proposed to explain the 
mechanisms by which heterogeneous serotype DV 
infection  can  induce  DHF/DSS  in  secondary 
infection
[5, 6]. According to the ADE hypothesis, the 
antibody generated during primary dengue infection can 
neutralize only DV with the same serotype but not 
those with different serotypes during secondary 
infection. In addition, the non-neutralizing antibodies 
may increase the virus uptake by macrophages through 
Fc receptor and even worsen the disease. However, 
antibody against DV pre M protein (anti-pre M Ab) can 
also augment dengue virus infection in a concentration-
dependent but serotype and FcR-independent manner
[7]. 
  Macrophage migration inhibitory factor (MIF) is a 
cytokine important in the modulation of inflammatory 
and immune responses
[8]. MIF is released by different 
cells in many tissues in response to a variety of 
stimuli
[9]. Once released, MIF augments the secretion of 
TNF-α and counteracts the anti-inflammatory action of 
glucocorticoids
[10]. Interestingly, low concentrations of 
glucocorticoids induce rather than inhibit MIF 
production in macrophages
[11]. In our previous study
[12], Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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we found that serum levels of MIF were correlated with 
disease severity in dengue patients. The mechanism that 
induces MIF production during DV infection is unclear, 
however. In this study, we show that DV infection of 
the human epithelial cell line A548 directly induced 
MIF production via NF-κB activation. We also 
explored the effects of DV infection on the production 
of MIF in other human cell lines, as well as in primary 
cells such as human umbilical vein endothelial cells 
(HUVEC) and peripheral blood mononuclear cells 
(PBMC), with or without pre-existing antibodies 
against DV. 
 
MATERIAL AND METHODS 
 
Preparing virus stock and virus titration: Dengue 
type 2 (DV2) strain PL046 and JEV (strain RP-9) 
viruses were propagated in C6/36 cells. Briefly, 
monolayers of C6/36 were inoculated with the virus at a 
multiplicity of infection (MOI) of 0.1 and incubated at 
26°C and 5% CO2 for 5 days. The culture medium was 
harvested, and cell debris was removed using 
centrifugation at 900 ×  g  for 10 min. After further 
centrifugation at 16,000 ×  g for 10 min, the virus 
supernatant was collected and stored at  -80°C until use. 
Virus titer was determined using a plaque assay with 
the BHK-21 cell line. Briefly, a 10-fold serial dilution 
of virus was added to BHK-21 monolayer and then 
incubated at 37°C at 5% CO2 for 5 days. Plaque 
numbers were counted after crystal violet staining. UV 
inactivation of DV (UV-DV) was done in a UV 
crosslinker (Stratalinker; Stratagen, La Jolla, CA) using 
short wavelength ultraviolet radiation (UVC, 254 nm) 
at a distance of 5 cm for 30 min on ice, as previously 
described
[13]. 
 
Cell culture: A human lung cancer epithelial cell line 
(A549) and a human hepatoma cell line (HepG2) were 
cultured in DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen), and 2 mM L-glutamine. A human T cell 
line (Jurkat), a myelomonocytic cell line (K562), and a 
monocytic cell line (THP-1) were grown at 37°C in 5% 
CO2 in RPMI 1640 medium with 10% FBS. Human 
peripheral blood mononuclear cells (PBMC) from 
healthy blood donors with no antibodies against DV2 
were isolated using lymphocyte separation medium 
(Histopaque-1.077; Sigma-Aldrich Co., St Louis, MO). 
Human umbilical vascular endothelial cells (HUVEC) 
were isolated from human umbilical cord veins and 
cultured as previously described
[14]. 
Viral infection and ADE: Cells were pretreated with 
or without dexamethasone (Dex, 10
-6  M)             
(Sigma-Aldrich) or curcumin (Cur, 60 µM)        
(Sigma-Aldrich) for 1 h before incubation with DV2 at 
an MOI of 10 or as indicated. Viruses were allowed to 
be absorbed by the cells for 2 h at 37°C. After that, 
unbound viruses were removed by washing with 
medium. Infected cells and culture supernatants were 
collected at different time intervals. Human PBMC or 
THP-1 cells were infected with DV2 at the MOI of 10 
in the presence of the diluted dengue type 3 patient 
serum (1:6000) or anti-pre M monoclonal antibody 70-
21 (1 µg)
[7]. 
 
Immunofluorescent staining and flow cytometric 
assay: Cells (1 × 10
6) were infected with DV2 at an 
MOI of 10 for 24 h. After they had been incubated, the 
cells were fixed with 4% paraformaldehyde for 30 min 
and then permeabilized with 0.5% Triton X-100 for 10 
min. The cells were then washed with PBS and blocked 
with 0.05% BSA in PBS. Fixed cells were stained with 
primary antibody at 4°C for 1 h. After being washed, 
the cells were incubated with secondary antibody and 
observed under a fluorescent microscope (Olympus, 
Tokyo, Japan) or for FACSCalibur analysis (Becton 
Dickinson Immunocytometry Systems, San Jose, CA) 
and analyzed using WinMDI 2.8 software. Anti-dengue 
mAb (anti-E, anti-pre M, and anti-NS1, a gift from Dr. 
Huan-Yao Lei), MIF rabbit antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), and NF-κB p65 rabbit 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 
were used as primary antibodies. FITC-conjugated 
goat-polyclonal anti-mouse IgG antibody (1:200 
dilution; Jackson ImmunoResearch, West Grove, PA), 
Alexa Fluor 594 conjugate goat-polyclonal anti-Rabbit 
IgG antibody (1:200 dilution; Molecular Probes, Inc., 
Eugene, OR) or Alexa Fluor 488 conjugate             goat-
polyclonal anti-Rabbit IgG antibody (1:200 dilution; 
Molecular Probes) were used as secondary antibodies. 
 
Reverse-transcription  polymerase  chain  reaction     
(RT-PCR): RNA was extracted using an isolation 
reagent (TRIzol; Invitrogen) and quantified at 260 nm. 
Reverse-transcription (RT) was done using a kit 
(Invitrogen) according to the manufacturer’s 
instructions. Glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) was a control. The primer 
sequences were: 
 
MIF (sense): 5’-TCCTTCTGCCATGCCGA-3’ 
MIF (antisense): 5’-TGCGGCTCTTAGGCGAAGGT-3’ 
GADPH (sense): 5’-CACGGCAAGTTCAATGGCACA-3’; 
GADPH (antisense): 5’-GAATTGTGAGGGAGAGTGCTC-
3’. Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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  A total reaction volume of 20 µl contained 4 µl of 
RT product, 2.5 units of Taq DNA polymerase, 20 µM 
of dNTP, 0.1 µM of primer, and 1× Taq DNA 
polymerase buffer (Promega, Madison, WI). The 
reaction mixture was incubated in a thermocycler 
(Perkin-Elmer,  Fremont,  CA)  programmed  to           
pre-denature at 95°C for 5 min, denature at 95°C for 30 
s, anneal at 56°C for 45 s, and extend at 72°C for 1 min. 
for a total of 30 cycles. After the last cycle, the 
resulting mixture was incubated at 72°C for 7 min and 
cooled to 4°C. 
 
ELISA for cytokines: Cells (1 × 10
6) were infected 
with DV2 or UV-DV2 at an MOI of 10, as described 
above. Culture supernatants were collected at different 
intervals post-infection as indicated. The concentrations 
of MIF in the supernatants as well as in patient sera 
were determined using ELISA kits (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s 
instructions. 
 
MIF promoter-luciferase vector: From -1170 to +3-
bp of the human MIF promoter was PCR-amplified 
from genomic DNA (Jurkat cells) and subsequently 
cloned into pGL2 Basic (Promega) between the Xho I 
and Hind III sites to generate pMIF-luc. The sequences 
of the primers used in the PCR were the following: 
 
Primer-1, 5’-CTCGAGCTGCAGGAACCAATACCCAT-3’  
and  
Primer-2, 5’-AAGCTTGGCATGATGGCAGAAGGACC-3’. 
 
  The PCR conditions were 94°C for 5 min and then 
35 cycles at 94°C, 55°C and 72°C, each for 1 min. The 
PCR product was gel-purified and then digested by the 
restriction enzymes XhoI and HindIII ligated into the 
XhoI/HindIII sites of the pGL2 vector (Novagen, 
Madison, WI) to produce pGL2-MIF. The nucleotide 
sequence was confirmed using DNA sequence analysis. 
 
Transient cell-transfection and assay for luciferase 
activity: The cells were transfected with reporter 
plasmid and the internal control vector thymine kinase. 
After transient transfection, the cells were treated with 
DV2 for two days and then cultured in an atmosphere 
of 5% CO2 and 95% air at 37°C for 72 h. The cells were 
then harvested, and luciferase activities in the cell 
extracts  were  determined  using  a  Lucilight          
(Perkin-Elmer Life Sciences, Norwalk, CT) and read 
using a microplate scintillation and luminescence 
counter (TopCount NXT; Perkin-Elmer). All 
experiments were performed on triplicate samples and 
were independently repeated four times. 
  The promoter regions were repeated and turned 
into a luciferase reporter system. For the reporter assay, 
plasmid DNA was transfected into A549 cells using a 
cationic lipid reagent (Lipofectamine 2000; Invitrogen). 
In brief, cells were plated 24 h before transfection at a 
density of 1 × 10
5 cells/well (12-well plate). Five hours 
after transfection, the cells were replenished with 
culture medium and then incubated for various time 
periods. NF-κB-Luc luciferase reporter plasmid was 
from Clontech (Palo Alto, CA). The pRL-TK reporter 
construct (Promega), encoding Renilla luciferase driven 
by the HSV thymidine kinase promoter, was used as an 
internal control. Five hours post-transfection, cells were 
infected with DV2 or JEV (MOI = 10). At various 
times after infection, cell lysates were collected for 
dual-luciferase assays (Promega). Relative firefly 
luciferase activity was normalized to Renilla luciferase 
activity. 
 
Statistical analysis: Data are expressed as means ± SD. 
Student’s t test was used to analyze the significance of 
the difference between the test and the control groups. 
Statistical significance was set at P < 0.05. 
 
RESULTS  
 
DV2 infection induced MIF production in A549 
cells: To assess whether DV2 infection induces MIF 
production, we incubated A549 cells with DV2 for 48 h 
at an MOI of 10. Antibody against DV2 E antigen as 
well as antibody against MIF were used to double-stain 
both DV2 and MIF in cells. DV2 infection of A549 
cells was confirmed by the presence of E antigen in the 
cytoplasmic region of the infected cells. Furthermore, 
DV infection induced MIF expression in both the nuclei 
and cytoplasm of these cells (Figure 1A). On the other 
hand, MIF expression in mock-infected cells was found 
only in some cells and mainly in nuclei (Figure 1B). 
MIF was time- and dose-dependently released from 
DV-infected A549 cells: We next assessed whether 
DV2-infection-induced MIF production is time- and 
dose-dependent. No significant increase of MIF release 
was found  in DV2-infected A549 cells than in mock-
infected cells after 24 h of infection (Figure 2A); 
however, after 48 h of infection, the MIF concentration 
were significantly elevated in the supernatants of the 
DV2-infected cells but not in the mock-infected cells. 
DV2-infected A549 cells continued to release MIF for 
at least 72 h after DV infection (Figure 2A). MIF was 
also dose-dependently secreted  after  DV  infection  
(Figure 2B),  but   A549 cells Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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(A) DV2 infected A549 cells 
          Anti-E                      MIF  DAPI 
   
(B) Mock-infected A549 cells 
  Anti-E   MIF   DAPI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1:  DV2 infection induced MIF production in A549 cells. A549 cells were mock- or DV2-infected for 48 h 
(MOI = 10). The cells were then immunostained with anti-MIF (Alexa 594 conjugated secondary 
antibodies), anti-DV-2 E (FITC-conjugated secondary antibodies) antibodies, and DAPI to stain nuclei, as 
described in Materials and Methods. Cells were observed using fluorescent microscopy at ×400 
magnification. 
 
treated with UV-inactivated DV did not release a 
significant amount of MIF (Figure 2B). 
 
DV infection increased the MIF mRNA expression 
of A549 cells: To further understand whether MIF 
production was caused by a de novo synthesis of MIF 
RNA or the release of pre-formed cytokines stored 
inside cells, we used RT-PCR to analyze the MIF 
mRNA levels in DV-infected A549 cells. Although 
background expression of MIF mRNA levels was 
detected in the mock-treated cells (Figure 3A). the 
expression of MIF RNA was dramatically increased in 
DV2-infected cells. Transfecting A549 cells with a 
construct containing the MIF promoter and luciferase 
reporter gene provided further evidence that DV 
infection activates MIF-gene transcription. When A549 
cells were transiently transfected with an        MIF-Luc 
minimal promoter/reporter and analyzed for luciferase 
expression 48 h after infection, the luciferase activity of 
DV2-infected cells increased 1.75 times compared with 
mock-infected cells (Figure 3B) which confirmed that 
DV2 infection induced MIF gene activation. JEV-
infected A549 cells, on the other hand, did not induce 
MIF gene activation. 
 
NF-κB was activated after DV infection of A549 
cells: Because NF-κB activation is implicated in 
activating many pro-inflammatory cytokines, we next 
examined   whether  NF-κB  was  activated  after  A549 Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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(B) 
Fig.  2.    DV2 time and dose-dependently induced MIF 
production in A549 cells. (A) A549 were 
infected with DV2 (MOI = 10) or mock-
infected. Supernatants were harvested at 24, 48, 
and 72 h, and the amount of MIF released into 
the supernatants was assessed using ELISA. (B) 
A549 cells were infected with DV2 at MOIs of 
1, 5, 10, and 20 or stimulated with UV-
inactivated-DV2 at an MOI of 10. Supernatants 
were collected after 72 h and the amount of MIF 
was assessed using ELISA. 
 
cells had been infected with DV2. We first assessed 
whether DV2 infection had activated an NF-κB 
dependent reporter gene. Luciferase expression in     
DV2-infected cells increased 1.87 times compared with 
mock-infected cells (Figure 4A) but not in cells 
transfected with UV-inactivated DV2. 
  We next sought further evidence of NF-κB 
activation by assessing NF-κB nuclear translocation 
using immunostaining to detect p65/NF-κB.  
      MOCK     DV2  
 
 
 
MIF 
 
GADPH 
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
Fig. 3. DV2 infection activated MIF gene transcription 
in A549 cells. (A) MIF mRNA expression in 
DV2-infected A549 cells. RNA was extracted 
and MIF expression was analyzed using semi-
quantitative RT-PCR with specific primers for 
MIF (see Materials and Methods) using 30 
amplification cycles. The gene expression of 
GADPH was used as the internal control. Lane 
1: Mock (uninfected). (B)A549 cells were 
transfected with MIF-Luc (0.5 µg) and pRL-TK 
(0.05  µg) for 24 h, then infected with DV2 
(MOI = 10) for 48 h. The cell lysates were then 
harvested for dual-luciferase assays. Luciferase 
activity is shown as the relative counts per 
second of firefly luciferase normalized to 
Renilla luciferase. 
 
Immunofluorescent  microscopy  analysis  of            
DV2-infected and mock-infected cells. DV2-infected 
A549 cells showed clear evidence of NF-κB nuclear 
translocation, but mock-infected cells did not (Figure 
4B). To further confirm NF-κB translocation occurred 
in DV2-infected cells, A549 cells were double stained 
with DV E protein and NF-κB. Co-localization of DV E 
protein  in  the  cytoplasm  and  NF-κB  in  the 
 Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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(B) 
 Anti-E  Anti  NFκB    Merge 
   
 
   
 
MOCK 
 
 
 
 
 
 
 
 
 
 
 
 
DV2 
 
 
 
 
 
 
 
 
Fig. 4.  NF-κB activation in DV2-infected A549 cells. (A) A549 cells were transfected with NF-κB-Luc (0.5 µg) 
and pRL-TK (0.05 µg) for 24 h, and then infected with DV2 (MOI = 10) for 48 h. The cell lysates were then 
harvested for dual-luciferase assays. Luciferase activity is shown as the relative counts per second of firefly 
luciferase normalized to Renilla luciferase. (B) A549 cells were mock-infected or DV2-infected for 48 h 
(MOI = 10). The cells were then immunostained with anti-NF-κB p65 and anti-DV-2 E antibody, as 
described in Materials and Methods. Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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Fig. 5.  Effects of dexamethasone and curcumin on the 
production of MIF induced by DV2 infection 
of A549 cells. A549 cells were incubated with 
or without DV2 or UV-V2, as described in 
Materials and Methods, with or without (A) 
dexamethasone (Dex, 10
−6 M) or (B) curcumin 
(Cur, 60 µM). The levels of MIF in the 
supernatants were assayed using ELISA.       
***P < 0.001. 
nuclei of the same cells was clearly evident under 
fluorescent microscopy (Figure 4B). 
 
Inhibiting NF-κB blocked DV2-infection-induced 
MIF production in A549 cells: To assess whether           
NF-κB activation was involved in MIF production, we 
used two NF-κB activation inhibitors, 
dexamethasone
[15] and curcumin
[16]. We found that 
DV2-infected A549 cells treated with 10
−6 M of 
dexamethasone or 50 µg/ml of curcumin significantly 
(P < 0.001) inhibited MIF production (Figure 5). We 
tested the effect of dexamethasone and curcumin at 
these  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  6.    DV2 infection in different types of cells 
induced different capacities to produce MIF. 
(A) Human Jurkat, K562 HepG2, and A549 cell 
lines, as well as primary PBMCs and HUVECs, 
were infected with DV2 at an MOI of 10. The 
levels of MIF in the supernatants were assayed 
at 48 h post-infection using ELISA 
 
concentrations because they had previously proved to 
have the maximal effect without any cell toxicity in 
A549 cells
[15, 16]. 
 
Different cells had different abilities to release MIF 
after DV2 infection: Because human mononuclear, 
endothelial, and hepatic cells are all permissive to DV2 
infection in vitro, we tested whether DV2 infection of 
these cells induces MIF production. A significant 
increase in MIF release was found in human endothelial 
cells, HUVECs, K562 cells (a human erythroleukemia 
cell line, and Jurkat cells 48 h after DV2 infection. 
However, no significant increase of MIF release was 
found in HepG2 cells or PBMCs (Figure 6). 
 
Antibodies against DV increased DV2 infection and 
MIF production in human immune cells: Because 
monocytes and macrophages are probably the primary 
targets of DV infection in vivo, and because antibodies 
against DV have been reported to increase DV 
infection, we tried to assess whether antibodies against 
DV in these cells increases MIF production. We first 
used the human monocytic cell line THP-1 and a pre M 
monoclonal antibody, 70-21, which has been reported 
to increase DV infection. After we double-stained     
THP-1 cells with antibodies against DV E antigen and 
MIF, we used flow cytometry to analyze the effects. 
We found a significant increase of DV and MIF     
double-positive cells in the presence of anti-pre M mAb 
but  not  DV  infection  alone  (50.04%  vs.  0.98%)         
(Figure 7A). We found a similar antibody-dependent 
increase in  MIF  production  in  PBMCs  infected  with 
 Am. J. Infect. Dis., 4 (1): 22-31, 2008 
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(A) 
  Mock   DV2   DV2+Anti-PrM Ab 
    
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  7.    Antibody-enhanced DV2 induced MIF production in THP1 cells and PBMCs. (A) THP-1 cells were 
infected with DV2 at an MOI of 10 in the presence of anti-pre M (70-21) (10 µg) antibody. The cells were 
then immunostained with anti-MIF (Alexa 594 conjugated secondary antibodies) and anti-DV-2 E (Alexa 
Fluor 488-conjugate secondary antibodies). (B) Human PBMCs were infected with DV2 at an MOI of 10 in 
the presence of diluted dengue type 3 immune serum (1:6000) or anti-pre M (70-21) (10 µg) antibody. The 
cells were then immunostained with anti-MIF (Alexa Fluor 594-conjugate secondary antibodies). 
Monocytes in PBMCs were gated and analyzed for antibody binding using flow cytometry as described in 
Materials and Methods. 
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DV2 in the presence of anti-pre M antibodies or serum 
from dengue patients (Figure 7B). Anti-pre M antibody 
alone, however, had no effect on MIF expression in 
PBMCs. 
 
DISCUSSION 
 
  An increase in the serum level of MIF is correlated 
with the disease severity in a dengue patient. However, 
the cellular source and molecular mechanism involved 
in the induction of MIF during DV2 infection are 
unclear. In the present study, we investigated the ability 
and molecular mechanism of DV2 infection to induce 
MIF production in human epithelial A549 cells. We 
found that DV2 infection, but not UV-inactivated-DV2 
stimulation, dose- and time-dependently induced MIF 
production, which indicated that active DV2 replication 
is required to induce MIF release. We also found that 
not all virus infections of A549 cells can induce MIF 
production: Japanese encephalitis virus (JEV) did not 
activate MIF gene promoter activity in A549 cells. 
  Activating MIF gene transcription requires the 
participation of several transcription factor complexes 
such as NF-κB
[9]. The activation of     NF-κB occurs via 
the phosphorylation and degradation of an inhibitory 
protein, IκB, which releases NF-κB from the cytoplasm 
and allows its translocation into the nucleus. The 
nuclear translocation of NF-κB p65 was evident in 
DV2-infected A549 cells, in marked contrast to the 
mock-infected cells, in which NF-κB p65 was 
predominantly in the cytoplasmic region. DV2-
infection-induced MIF production is NF-κB-activation-
dependent was further supported by the inhibition of 
MIF release in the presence of the NF-κB inhibitors 
dexamethasone and curcumin. Although JEV infection 
of A549 cells also activated NF-κB
[13], we found no 
MIF promoter activation in JEV-infected A549 cells. 
Therefore, DV2-infection-induced NF-κB activation is 
required but not sufficient to turn on MIF gene 
expression. 
  We also found that DV2 infection, but not                 
UV-inactivated-DV2 stimulation, dose-dependently 
induced MIF production in human endothelial cells, as 
it did in A549 cells. However, in cells from the human 
hepatoma HepG2 cell line, which is also permissive to 
DV2 infection
[17], DV2 infection did not induce the 
release of MIF. Therefore, not all cells permissive to 
DV2 infection will release MIF after DV2 infection. 
Human blood mononuclear cells, which are thought to 
be the main target of DV2 in vivo, show a different 
susceptibility to DV2 infection and MIF production in 
vitro. Both the Jurkat T cell line and the 
myelomonocytic K562 cell line are highly susceptible 
to DV2 infection and show high percentage of 
infection
[18, 19]. However, the Jurkat cells release 
approximately four times more MIF than do K562 cells. 
This suggests that DV2 infection induces different 
amount MIF in different cells. Human monocytic     
THP-1 cell line and peripheral blood mononuclear cells, 
on the other hand, showed a smaller percentage of 
infection and no detectable MIF release in the absence 
of antibodies against DV2. 
  Antibody-increased DV2 infection in human 
macrophages in vitro has long been reported 
[5]. In the 
present study, we further showed that, in the presence 
of such antibodies, either a monoclonal pre M antibody 
or patient  serum, MIF production was also upregulated 
in the DV2-infected cells. These results may explain 
why secondary infection with DV2 causes more severe 
DHF/DSS and why higher levels of MIF are found in 
these patients. 
  In summary, the present study shows that DV2 
infection of cells induced MIF production in a NF-κB 
dependent manner. Further study to understand the 
mechanism and the role of MIF production in the 
immunopathogenesis of DHF/DSS may lead to the 
development of better therapeutic drugs against 
DHF/DSS. 
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